IL5 and asthma: In particular, the drug led to a suspension of oral corticosteroids in all the subjects treated with chronic long-term OCS treatment as well as a considerable reduction in asthma exacerbation events, and a significant eosinophil reduction, which is the principal mepolizumab pharmacological effect as an anti-IL5 strategy.